Monday's Underperforming Sectors: Healthcare Providers, Rubber, and Plastics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy SGRY?
Source: NASDAQ.COM
Market Performance: Rubber and plastics shares are lagging the market, down approximately 1.8% on Monday.
Key Contributors: Loop Industries saw a significant drop of about 15.7%, while Lightwave Logic decreased by around 5.6%.
Sector Laggards: The hospital and medical practitioners sector is also mentioned as a laggard alongside rubber and plastics.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SGRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SGRY
Wall Street analysts forecast SGRY stock price to rise
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 15.500
Low
18.00
Averages
26.30
High
36.00
Current: 15.500
Low
18.00
Averages
26.30
High
36.00
About SGRY
Surgery Partners, Inc. is a healthcare services company. The Company, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The Company operates through the Surgical Facility Services segment, which includes the operation of ambulatory surgery centers (ASCs), surgical hospitals, anesthesia services, urgent care facilities and multi-specialty physician practices. Its surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology (GI) and general surgery. The Company operates a portfolio of 162 surgical facilities comprised of 143 ASCs and 19 surgical hospitals. The Company is focused on surgical services businesses in the United States, with over 250 locations in 30 states, including short-stay surgical hospitals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Surgery Partners Reports Disappointing Q4 Results and Cautious 2026 Outlook
- Earnings Miss: Surgery Partners reported adjusted earnings of 12 cents per share for Q4, significantly below the consensus estimate of 30 cents, indicating challenges in the current economic landscape.
- Sales Growth: While sales increased by 2.4% year-over-year to $885 million, surpassing the consensus of $866.47 million, same-facility revenue growth of 3.5% and a 2.1% increase in revenue per case highlight ongoing competitive pressures.
- Declining Cash Flow: Operating cash flow fell to $103.4 million in Q4, down from $111.4 million a year ago, reflecting operational strain on the company.
- Cautious 2026 Outlook: The company expects fiscal 2026 sales between $3.35 billion and $3.45 billion, below the consensus of $3.56 billion, indicating a cautious stance on future market conditions.
See More
Ouster Inc Reports Strong Q4 Results, Shares Surge
- Strong Performance: Ouster Inc reported fourth-quarter revenue of $62.18 million, surpassing analyst expectations of $41.1 million, indicating robust market performance that is likely to boost investor confidence.
- Loss Improvement: The company reported a fourth-quarter loss of six cents per share, significantly better than the expected loss of 35 cents, demonstrating substantial progress in cost control and operational efficiency.
- Stock Price Surge: Ouster's shares jumped 13.8% to $23.04 in pre-market trading, reflecting a positive market reaction to its financial results, which may attract more investor interest.
- Optimistic Outlook: Ouster issued first-quarter sales guidance above estimates, signaling strong future prospects that could further drive stock price increases and enhance market confidence in its growth trajectory.
See More
Surgery Partners Q4 Earnings Report Analysis
- Earnings Miss: Surgery Partners reported a Q4 non-GAAP EPS of $0.12, missing expectations by $0.18, indicating pressure on profitability that may affect investor confidence.
- Modest Revenue Growth: The company achieved revenue of $885 million, up 2.4% year-over-year, surpassing expectations by $18.46 million; however, the limited growth suggests challenges from increased competition and rising costs.
- Debt Financing Initiative: A subsidiary of Surgery Partners priced $425 million in add-on notes, which will support the company's expansion plans, although the increased debt may pose risks to future financial health.
- Market Reaction Insight: Despite revenue exceeding expectations, the earnings miss could pressure the stock price in the short term, prompting investors to monitor the company's strategies for improving profitability and adapting to market changes.
See More
Surgery Partners to Release Q4 2025 Results and Host Conference Call
- Earnings Release Schedule: Surgery Partners plans to release its Q4 2025 financial results after market close on March 2, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Timing: The subsequent conference call is scheduled for March 3, 2026, at 8:30 a.m. (Eastern Time), providing investors with a direct opportunity to engage with management and strengthen the connection between the company and its investors.
- Dial-in Information: Investors can join the call using the domestic dial-in number 1-877-451-6152 or the international number 1-201-389-0879, ensuring broad participation and reflecting the company's focus on investor relations.
- Replay Availability: The call replay will be available three hours after the meeting and until March 17, 2026, enhancing information accessibility and demonstrating the company's attentiveness to investor needs.
See More
Irenic Capital Management Cuts Stake in Surgery Partners by Over 1 Million Shares
- Stake Reduction: Irenic Capital Management sold 1,047,583 shares of Surgery Partners in Q4 2025, valued at approximately $19.25 million, indicating a loss of confidence as the remaining stake now represents only 0.09% of its $1.49 billion assets under management.
- Financial Performance: Despite the sell-off, Surgery Partners reported a 6.6% increase in Q3 revenue to $821.5 million, with Adjusted EBITDA rising 6.1% to $136.4 million, suggesting that operationally the company remains stable and resilient.
- Market Performance Analysis: As of February 17, 2026, Surgery Partners' stock price stood at $15.60, reflecting a 39.7% decline over the past year, significantly underperforming the S&P 500 by 51.61 percentage points, which raises concerns about its growth prospects.
- Debt Risk Consideration: The company's net debt to EBITDA ratio is approximately 4.2x, and in the context of a high interest rate environment, this leverage could amplify risks for investors, thereby affecting market confidence in its stock.
See More
Surgery Partners Announces $425 Million Private Debt Offering Pricing
Private Offering Announcement: Surgery Partners (SGRY) announced that its Surgery Center subsidiary has priced a private offering.
Financial Implications: The details regarding the amount raised and the intended use of proceeds from the offering were not specified in the announcement.
See More
Surgery Partners Reports Disappointing Q4 Results and Cautious 2026 Outlook
- Earnings Miss: Surgery Partners reported adjusted earnings of 12 cents per share for Q4, significantly below the consensus estimate of 30 cents, indicating challenges in the current economic landscape.
- Sales Growth: While sales increased by 2.4% year-over-year to $885 million, surpassing the consensus of $866.47 million, same-facility revenue growth of 3.5% and a 2.1% increase in revenue per case highlight ongoing competitive pressures.
- Declining Cash Flow: Operating cash flow fell to $103.4 million in Q4, down from $111.4 million a year ago, reflecting operational strain on the company.
- Cautious 2026 Outlook: The company expects fiscal 2026 sales between $3.35 billion and $3.45 billion, below the consensus of $3.56 billion, indicating a cautious stance on future market conditions.
See More
Ouster Inc Reports Strong Q4 Results, Shares Surge
- Strong Performance: Ouster Inc reported fourth-quarter revenue of $62.18 million, surpassing analyst expectations of $41.1 million, indicating robust market performance that is likely to boost investor confidence.
- Loss Improvement: The company reported a fourth-quarter loss of six cents per share, significantly better than the expected loss of 35 cents, demonstrating substantial progress in cost control and operational efficiency.
- Stock Price Surge: Ouster's shares jumped 13.8% to $23.04 in pre-market trading, reflecting a positive market reaction to its financial results, which may attract more investor interest.
- Optimistic Outlook: Ouster issued first-quarter sales guidance above estimates, signaling strong future prospects that could further drive stock price increases and enhance market confidence in its growth trajectory.
See More
Surgery Partners Q4 Earnings Report Analysis
- Earnings Miss: Surgery Partners reported a Q4 non-GAAP EPS of $0.12, missing expectations by $0.18, indicating pressure on profitability that may affect investor confidence.
- Modest Revenue Growth: The company achieved revenue of $885 million, up 2.4% year-over-year, surpassing expectations by $18.46 million; however, the limited growth suggests challenges from increased competition and rising costs.
- Debt Financing Initiative: A subsidiary of Surgery Partners priced $425 million in add-on notes, which will support the company's expansion plans, although the increased debt may pose risks to future financial health.
- Market Reaction Insight: Despite revenue exceeding expectations, the earnings miss could pressure the stock price in the short term, prompting investors to monitor the company's strategies for improving profitability and adapting to market changes.
See More
Surgery Partners to Release Q4 2025 Results and Host Conference Call
- Earnings Release Schedule: Surgery Partners plans to release its Q4 2025 financial results after market close on March 2, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Timing: The subsequent conference call is scheduled for March 3, 2026, at 8:30 a.m. (Eastern Time), providing investors with a direct opportunity to engage with management and strengthen the connection between the company and its investors.
- Dial-in Information: Investors can join the call using the domestic dial-in number 1-877-451-6152 or the international number 1-201-389-0879, ensuring broad participation and reflecting the company's focus on investor relations.
- Replay Availability: The call replay will be available three hours after the meeting and until March 17, 2026, enhancing information accessibility and demonstrating the company's attentiveness to investor needs.
See More
Irenic Capital Management Cuts Stake in Surgery Partners by Over 1 Million Shares
- Stake Reduction: Irenic Capital Management sold 1,047,583 shares of Surgery Partners in Q4 2025, valued at approximately $19.25 million, indicating a loss of confidence as the remaining stake now represents only 0.09% of its $1.49 billion assets under management.
- Financial Performance: Despite the sell-off, Surgery Partners reported a 6.6% increase in Q3 revenue to $821.5 million, with Adjusted EBITDA rising 6.1% to $136.4 million, suggesting that operationally the company remains stable and resilient.
- Market Performance Analysis: As of February 17, 2026, Surgery Partners' stock price stood at $15.60, reflecting a 39.7% decline over the past year, significantly underperforming the S&P 500 by 51.61 percentage points, which raises concerns about its growth prospects.
- Debt Risk Consideration: The company's net debt to EBITDA ratio is approximately 4.2x, and in the context of a high interest rate environment, this leverage could amplify risks for investors, thereby affecting market confidence in its stock.
See More
Surgery Partners Announces $425 Million Private Debt Offering Pricing
Private Offering Announcement: Surgery Partners (SGRY) announced that its Surgery Center subsidiary has priced a private offering.
Financial Implications: The details regarding the amount raised and the intended use of proceeds from the offering were not specified in the announcement.
See More
